Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. Check out my ...

Inovio (INO) announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent ...

Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 American Association for Cancer Research – Immuno-Oncology Discovery ...

PLYMOUTH MEETING, Pa. - INOVIO (NASDAQ: INO), a biotechnology company with a market capitalization of approximately $69 million, has announced positive results from a Phase 1/2 clinical trial of ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

“These medicines will give people more treatment options and help them to live well for longer,” says Pharmac’s Director Equity and Engagement, Dr Nicola Ngawati. “We expect about 180 people will ...

Precigen, Inc. (NASDAQ:PGEN), a biotechnology company specializing in gene and cell therapies with a market capitalization of $398.3 million, is on the cusp of a significant transformation as it ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to ...

Recurrent respiratory papillomatosis (RRP) is a disease of the upper airway presenting with exophytic wart-like lesions. These lesions are considered benign with less than a 1–5% chance of malignant ...

Johns Hopkins laryngologist Simon Best outlines a new treatment option for patients with recurrent respiratory papillomatosis, a chronic HPV disease that has traditionally required repeated surgical ...

PRGN-2012 is under clinical development by Precigen and currently in Phase III for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma). According to GlobalData, ...

Papillomatosis index is the ratio of the length of the dermal-epidermal junction to the surface length of the epidermis. For Ki-67 staining, heat-induced epitope retrieval was performed in EDTA buffer ...